Literature DB >> 34608074

Is there a role for neoadjuvant anti-PD-1 therapies in glioma?

Lu Sun1, Thomas J Lai, Robert M Prins.   

Abstract

PURPOSE OF REVIEW: In this review, we summarized recent findings that highlight the progress for checkpoint blockade immunotherapy in glioblastoma (GBM) patients. RECENT
FINDINGS: We reviewed new data from our group and others that suggest that the timing of when immunotherapy is applied can impact the antitumor immune response and, potentially, the ultimate clinical benefit of patients.
SUMMARY: The neoadjuvant priming and expansion of exhausted T cells within the GBM microenvironment, followed by the removal of an immune suppressive tumor microenvironment through surgical resection, may lead to enhanced antitumor immune responses that are beneficial clinically. As such, neoadjuvant immunotherapeutic approaches and rational combinations may be helpful scientifically to understand how immunotherapeutic interventions influence the tumor microenvironment, as well benefit the patients.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34608074      PMCID: PMC8595846          DOI: 10.1097/WCO.0000000000000992

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  33 in total

1.  What is the blood-brain barrier (not)?

Authors:  Ingo Bechmann; Ian Galea; V Hugh Perry
Journal:  Trends Immunol       Date:  2006-11-30       Impact factor: 16.687

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Authors:  Kurt A Schalper; Maria E Rodriguez-Ruiz; Ricardo Diez-Valle; Alvaro López-Janeiro; Angelo Porciuncula; Miguel A Idoate; Susana Inogés; Carlos de Andrea; Ascensión López-Diaz de Cerio; Sonia Tejada; Pedro Berraondo; Franz Villarroel-Espindola; Jungmin Choi; Alfonso Gúrpide; Miriam Giraldez; Iosune Goicoechea; Jaime Gallego Perez-Larraya; Miguel F Sanmamed; Jose L Perez-Gracia; Ignacio Melero
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

6.  Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

Authors:  John de Groot; Marta Penas-Prado; Kristin Alfaro-Munoz; Kathy Hunter; Be Lian Pei; Barbara O'Brien; Shiao-Pei Weathers; Monica Loghin; Carlos Kamiya Matsouka; W K Alfred Yung; Jacob Mandel; Jimin Wu; Ying Yuan; Shouhao Zhou; Gregory N Fuller; Jason Huse; Ganesh Rao; Jeffrey S Weinberg; Sujit S Prabhu; Ian E McCutcheon; Frederick F Lang; Sherise D Ferguson; Raymond Sawaya; Rivka Colen; Shalini S Yadav; Jorge Blando; Luis Vence; James Allison; Padmanee Sharma; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

Review 7.  Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.

Authors:  Anna C Filley; Mario Henriquez; Mahua Dey
Journal:  Oncotarget       Date:  2017-10-06

8.  Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.

Authors:  Ester Gangoso; Benjamin Southgate; Leanne Bradley; Stefanie Rus; Felipe Galvez-Cancino; Niamh McGivern; Esra Güç; Chantriolnt-Andreas Kapourani; Adam Byron; Kirsty M Ferguson; Neza Alfazema; Gillian Morrison; Vivien Grant; Carla Blin; IengFong Sou; Maria Angeles Marques-Torrejon; Lucia Conde; Simona Parrinello; Javier Herrero; Stephan Beck; Sebastian Brandner; Paul M Brennan; Paul Bertone; Jeffrey W Pollard; Sergio A Quezada; Duncan Sproul; Margaret C Frame; Alan Serrels; Steven M Pollard
Journal:  Cell       Date:  2021-04-09       Impact factor: 41.582

Review 9.  The immune landscape of common CNS malignancies: implications for immunotherapy.

Authors:  Martina Ott; Robert M Prins; Amy B Heimberger
Journal:  Nat Rev Clin Oncol       Date:  2021-06-11       Impact factor: 66.675

Review 10.  An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Authors:  Martha R Neagu; David A Reardon
Journal:  Curr Treat Options Oncol       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.